Pfizer Announces Agreement with Gilead To Manufacture Remdesivir For Treatment Of Covid-19

 

Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19. Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer’s McPherson, Kansas facility to manufacture and supply remdesivir for Gilead. Source Investor Relations Pfizer

Granted Emergency Use Authorization (EUA) by the FDA for the treatment of COVID-19 VEKLURY® (remdesivir) is authorized for use under an EUA only for the treatment of patients with suspected or laboratory-confirmed SARS-CoV-2 infection and severe COVID-19. Severe disease is defined as patients with an oxygen saturation (SpO2) ≤94% on room air or requiring supplemental oxygen, mechanical ventilation, and/or extracorporeal membrane oxygenation (ECMO). VEKLURY is authorized for adult or pediatric patients who are admitted to a hospital and for whom use of an IV agent is clinically appropriate. VEKLURY must be administered intravenously. Source: Remdesivir

During his more than 25 years at Pfizer, Albert Bourla, Dvm, Ph.D  has built a diverse and successful career, holding a number of senior global positions across a range of markets and disciplines. Prior to taking the reins as CEO in January 2019, Albert served as the Pfizer’s Chief Operating Officer (COO) beginning in January 2018, responsible for overseeing the Company’s commercial strategy, manufacturing, and global product development functions.

Previously, from February 2016 to December 2017, Albert served as Group President of Pfizer Innovative Health, which comprised the Consumer Healthcare, Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease and Vaccines business groups. Source: Pfizer

Dexamethasone a miracle ‘breakthrough’ for seriously ill COVID-19 patients

Image Of A Massive Bat From Philippines Could Invade The World

Which drugs and therapies are proven to work, and which ones don’t, for COVID-19?

Comments


CWEB.com is not registered as an investment adviser with the U.S. Securities and Exchange Commission. Rather, CWEB.com relies upon the “publisher’s exclusion” from the definition of investment adviser as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.

Full Disclaimer

%d bloggers like this: